Cov644

RPE1-hTERT p53^−/− Cas9
(Zimmermann et al., 2018 (link)) and
293T cells were grown in DMEM supplemented with 10% FBS (Wisent
#080150), GlutaMAX (life Technologies #35050–061) and 1%
Pen/Strep (Wisent #450–201-EL). UWB1.28, SKOV3 and OV90 cells
were purchased from ATCC. UWB1.28 cells were grown in RPMI: MEGM (1:1)
supplemented with 3% FBS and 1% Pen/Strep. SKOV3 cells were grown in
McCoys 5a supplemented with 10% FBS and 1% Pen/Strep. OV90 cells were
grown in MCDB 105: Medium 99 (1:1) supplemented with 1% sodium
bicarbonate (0.75 g/L), 15% FBS and 1% Pen/Step. JHOS2 were purchased
from Riken BRC and grown in DMEM: F-12(1:1) supplemented with 10%FBS,
0.1mM NEAA. SUM149PT cells were purchased from Asterand BioScience and
grown in a DMEM/F12 medium mixture supplemented with 5% FBS, 1%
Pen/Strep, 1 μg/mL hydrocortisone and 5 μg/mL insulin.
COV362 and COV644 were purchased from Sigma and grown in DMEM
supplemented with 10% FBS and 1% Pen/Strep. RMUGS cells were purchased
from JCRC cell bank and grown in Ham’s 12 supplemented with 10%
FBS and 1% Pen/Strep. Wild-type and
BRCA2^−/−DLD-1 cells were purchased from Horizon and maintained in RPMI medium
supplemented with 10% FBS, 1% Pen/Strep and 2 mM sodium pyruvate. All
cell lines were grown at 37 °C and 5% CO2.